<DOC>
	<DOCNO>NCT00891267</DOCNO>
	<brief_summary>The purpose study study effect two dos olmesartan medoxomil amlodipine vascular marker hypertensive patient metabolic syndrome .</brief_summary>
	<brief_title>Effect Two Doses Olmesartan Medoxomil Amlodipine Vascular Markers Hypertensive Patients With Metabolic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female Europeans age 18 year hypertension , metabolic syndrome , modest inflammation Blood pressure great equal 130/85 mmHg AND hsCRP great equal 1.0 less 10.0 mg/dL AND least two ( 2 ) follow trait metabolic syndrome ( ATP III criterion ) : abdominal obesity : waist circumference great 102 cm men 88 cm woman ; triglyceride level great equal 150 mg/dL ; HDL le 40 mg/dL men le 50 mg/dL woman fast blood glucose great equal 110mg/dL Insulin depend diabetes type1 diabetes Severe resistant hypertension Patients secondary hypertension aetiology , renal disease , pheochromocytoma , Cushing 's syndrome Any acute chronic inflammatory disease Constant use lipidlowering agent ( eg statin , fibrates ) less 3 month study start Pregnant lactate female patient childbearing potential ( prerequisite : adequate contraception ) ; Patients serious disorder may limit ability evaluate efficacy safety trial drug ( )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Inflammatory marker</keyword>
	<keyword>Vascular protection</keyword>
	<keyword>OM Effect</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Hypertension</keyword>
</DOC>